New heterocyclic ligands for the adenosine receptors P1 and for the ATP receptors P2

Farmaco

Volumn 60, Issue 3, 2005, Pages 185-202

  Baraldi, Pier Giovanni ^a   Romagnoli, Romeo ^a   Tabrizi, Mojgan Aghazadeh ^a   Bovero, Andrea ^a   Preti, Delia ^a   Fruttarolo, Francesca ^a   Moorman, Allan R ^b   Borea, Pier Andrea ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b King Pharmaceutical R and D   (United States)

Author keywords

Adenosine; Heterocyclic; Ligands; P1 receptors; P2 receptors

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2 (3,4 DIMETHOXYPHENYL) N [5 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 1 METHYL 1H PYRAZOL 3 YL]ACETAMIDE; 2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 (3 PHENYLPROPYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 N (4 METHOXYPHENYLCARBAMOYL)AMINO 8 PROPYL 2 (2 FURYL)PYRAZOLO[4,3 E] 1,2,4 DIAZOLE[1,5 C]PYRIMIDINE; 6 N CYCLOPENTYLADENOSINE; ADENINE; ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; ADRENERGIC RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; HETEROCYCLIC COMPOUND; LIGAND; MRE 2028; MRE 2029; MRE 2030; MRE 3008; N (3,4 DIMETHOXYPHENYL) 2 [5 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 1 METHYL 1H PYRAZOL 3 YLOXY]ACETAMIDE; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; N BENZO[1,3]DIOXOL 5 YL 2 [5 (2,6 DIOXO 1,3 DIPROPYL 2,3,6,7 TETRAHYDRO 1H PURIN 8 YL) 1 METHYL 1H PYRAZOL 3 YLOXY]ACETAMIDE; NUCLEOTIDE; PIPERAZINE DERIVATIVE; PURINE P2 RECEPTOR; PURINE P2X RECEPTOR; PURINE P2X7 RECEPTOR; PURINE P2Y RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; URIDINE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CHO CELL; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; LIGAND BINDING; NEUROMODULATION; NONHUMAN; PROTEIN DETERMINATION; RECEPTOR AFFINITY; RECEPTOR SENSITIVITY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

EID: 15244353252     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.farmac.2004.09.007     Document Type: Short Survey

References (56)

1. B.B. Fredholm Nomenclature and classification of adenosine receptors Pharmacol Rev. 53 2001 527 552
2. B.B. Fredholm, G. Arslan, L. Haldner, B. Kull, G. Schulte, and W. Wasserman Structure and function of adenosine receptors and their genes Naunsyn-Schmiedberg4s Arch Pharmacol. 362 2000 364 374
3. J. Spychala Tumor-promoting functions of adenosine Pharmacol. Ther. 87 2000 161 173
4. G. Burnstock A Basis for Distinguishing Two Types of Purinergic Receptor, in Cell Membrane Receptors for Dugs and Hormones L. Bolis R.W. Straub 1978 Raven Press New York 107 118
5. N.J. Birdsall, F. Cohen, and S. Lazareno Regulation of G-protein-linked receptors Biochem. Soc. Trans. 23 1995 108 111
6. N.J. Birdsall, T. Farries, P. Gharagozloo, S. Kobayashi, and S. Lazareno Sugimoto. Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: functional studies M Mol. Pharmacol. 55 1999 778 786
7. J. Linden Allosteric enhancement of adenosine receptors Purinergic Approaches in Experimental Therapeutics 1997 K.A. Jacobson, M.F., Eds., Jarvis, Wiley-Liss New York 29 37
8. A. Christopoulos, A. Lanzafame, and F. Mitchelson Allosteric interactions at muscarinic cholinoceptors Clin. Exp. Pharmacol. Physiol. 25 1998 185 194
9. B.B. Fredholm Adenosine and neuroprotection Int. Rev. Neurobiol. 40 1997 259 280
10. R.F. Bruns, and J.H. Fergus Allosteric enhancement of adenosine A1 receptor binding and function by 2-amino-3-benzoylthiophenes Mol. Pharmacol. 38 1990 939 949
11. C.A. Kollias-Baker, J. Ruble, M. Jacobson, J.K. Harrison, M.J. Ozeck, J.C. Shryock, and L. Belardinelli Agonist-independent effect of an allosteric enhancer of the A1 adenosine receptor in CHO cells stably expressing the recombinant human A1 receptor J. Pharmacol. Exp. Ther. 281 1997 761 768
12. B. Musser, R.V. Mudumbi, J. Liu, R.D. Olson, and R.E. Vestal Adenosine A1 receptor-dependent and -independent effects of the allosteric enhancer PD 81,723 J. Pharmacol. Exp. Ther. 288 1999 446 454
13. P.G. Baraldi Thiophenes useful for modulating the adenosine receptor US Patent 5 1997 939 432
14. P.G. Baraldi, A.N. Zaid, I. Lampronti, F. Fruttarolo, M.G. Pavani, and M.A. Tabrizi Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor Bioorg. Med. Chem. Lett. 10 2000 1953 1957
15. Baraldi, P.G. Preparation of acyl-amino-(fused) thiophenes as allosteric adenosine receptor modulators. U.S. Pat. (20019 Appl. 20010047008.
16. P.A.M. Van der Klein, A.P. Kourounakis, and A.P. IJzerman Allosteric modulation of the adenosine A1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding J. Med. Chem. 42 1999 3629 3635
17. A.P. Kourounakis, C. Visser, M. de Groote, and A.P. IJzerman Allosteric modulation of the rat adenosine A1 receptor: differential effects on agonist and antagonist binding Drug Dev. Res. 51 2000 207 215
18. C.E. Tranberg, A. Zickgraf, B.N. Giunta, H. Luetjens, H. Figler, L.J. Murphree, R. Falke, H. Fleischer, J. Linden, P.J. Scammells, and R.A. Olsson 2-Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors J. Med. Chem. 45 2002 382 389
19. P.G. Baraldi, R. Romagnoli, M.G. Pavani, M.C. Nuñ ez, M. Aghazadeh Tabrizi, J.C. Shryock, E. Leung, A.R. Moorman, C. Uluoglu, V. Iannotta, S. Merighi, and P.A. Borea Synthesis and biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptor J. Med. Chem. 46 2003 794 809
20. P. Svenningson, C. Le Moine, G. Fisone, and B.B. Fredholm Distribution, biochemistry and function of striatal adenosine A2A receptors Prog. Neurobiol. 59 1999 355 396
21. E. Ongini, and B.B. Fredholm Pharmacology of adenosine A2A receptors Trends Pharmacol. Sci. 17 1996 364 372
22. P.G. Baraldi, B. Cacciari, and G. Spalluto Current developments of A2A adenosine recepto antagonists Curr. Med. Chem. 2 1995 707 722
23. E. Ongini, S. Dionisotti, S. Gessi, E. Irenius, and B.B. Fredholm Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors Naunyn Schmiedebergs Arch. Pharmacol. 59 1999 7 10
24. P.G. Baraldi, B. Cacciari, G. Spalluto, M.J. Pineda de las Infantas y Villatoro, C. Zocchi, S. Dionisotti, and E. Ongini Pyrazolo[4,3-e]-1,2,4- triazolo[1,5-c]pyrimidine derivatives: potent and selective A2A adenosine antagonists J. Med. Chem. 39 1996 1164 1171
25. C. Zocchi, E. Ongini, A. Conti, A. Monopoli, A. Negretti, P.G. Baraldi, and S. Dionisotti The non xanthine heterocyclic compound SCH 58261 is a new potent and selective A2A adenosine receptor antagonist J. Pharmacol. Exp. Ther. 276 1996 398 404
26. A.R. Carta, M. Aghazadeh Tabrizi, P.G. Baraldi, A. Pinna, P. Pala, and M. Morelli Exp. Neurol. 184 2003 679 687
27. P.G. Baraldi, B. Cacciari, and G. Spalluto Design, synthesis and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4- triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonist J. Med. Chem. 41 1998 2126 2133
28. P.G. Baraldi, B. Cacciari, R. Romagnoli, G. Spalluto, A. Monopoli, E. Ongini, K. Varani, and P.A. Borea 7 substituted 5-amino-2-(2-furyl)pyrazolo[4,3- e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility J. Med. Chem. 45 2002 115 126
29. P.G. Baraldi, B. Cacciari, R. Romagnoli, G. Spalluto, S. Moro, K.-N. Klotz, E. Leung, K. Varani, S. Gessi, S. Merighi, and P.A. Borea Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists: influence of the chain at the N8 pyrazolo nitrogen J. Med. Chem. 43 2000 4768 4780
30. P.G. Baraldi, F. Fruttarolo, M.A. Tabrizi, D. Preti, R. Romagnoli, H. El-Kashef, A. Moorman, K. Varani, S. Gessi, S. Merighi, and P. Borea Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists J. Med. Chem. 46 2003 1229 1241
31. P.G. Baraldi, B. Cacciari, R. Romagnoli, G. Spalluto, K.N. Klotz, E. Leung, K. Varani, S. Gessi, S. Merighi, and P.A. Borea Pyrazolo[4,3-e]-1,2,4- triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists J. Med. Chem. 42 1999 4473 4478
32. P.G. Baraldi, B. Cacciari, R. Romagnoli, S. Meriggi, K. Varani, P.A. Borea, and G. Spallato A3 adenosine receptor ligands: history and perspectives Med. Res. Rev. 20 2000 103 128 Review
33. P.G. Baraldi, and P.A. Borea New potent and selective human adenosine A3 receptor antagonists Trends Pharmacol. Sci. 21 2000 456 459
34. 3 adenosine receptors J. Med. Chem. 39 1996 802 806
35. P.G. Baraldi, B. Cacciari, S. Moro, G. Spalluto, G. Pastorin, T. Da Ros, K.N. Klotz, K. Varani, S. Gessi, and P.A. Borea Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidine derivatives as human A3 adenosine receptor antagonists J. Med. Chem. 45 2002 770 780
36. P.G. Baraldi, B. Cacciari, R. Romagnoli, G. Spalluto, K.-N. Klotz, E. Leung, K. Varani, S. Gessi, S. Merighi, and P.A. Borea Pyrazolo [4,3-e]-1,2,4-triazolo [1,5-c]-pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists J. Med. Chem. 42 1999 4474 4478
37. 3 adenosine receptor and molecular modeling studies J. Med. Chem. 44 2001 2735 2742
38. P.G. Baraldi, B. Cacciari, R. Romagnoli, K. Varani, S. Gessi, S. Merighi, P.A. Borea, E. Leung, S.L. Hickey, and G. Spalluto Synthesis and preliminary biological evaluation of [3H]MRE3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors Bioorg. Med. Chem. Lett. 10 2000 209 211
39. Y.-C. Kim, Y. Karton, X.-D. Ji, N. Melman, J. Linden, and K.A. Jacobson Acyl hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptor Drug Dev. Res. 47 1999 178 188
40. K.A. Jacobson, A.P. Ijzerman, and J. Linden 1,3-Dialkylxanthie derivatives having high potency as antagonists at human A2B adenosine receptors Drug Dev. Res. 47 1999 45 53
41. Y.-C. Kim, M. De Zwart, L. Chang, S. Moro, J.K. Von Frijtag Drabbe Kunzel, N. Melman, A.P. Ijzerman, and K.A. Jacobson Derivatives of the triazoloquinazoline adenosine antagonists (CGS15943) having high potency at the human A2B and A3 receptor subtypes J. Med. Chem. 41 1998 2835 2845
42. T.R. Webb, D. Lvovskiy, S.-A. Kim, X. Ji, N. Melman, J. Linden, and K.A. Jacobson Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors Bioorg. Med. Chem. 11 2003 77 85
43. P.G. Baraldi, M. Aghazadeh Tabrizi, D. Preti, A. Bovero, R. Romagnoli, F. Fruttarolo, N. Abdel Zaid, A.R. Moorman, K. Varani, S. Gessi, S. Merighi, and P.A. Borea Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists J. Med. Chem. 47 2004 1434 1447
44. P.G. Baraldi, M. Aghazadeh Tabrizi, D. Preti, A. Bovero, R. Romagnoli, F. Fruttarolo, A.R. Moorman, K. Varani, S. Gessi, S. Merighi, and P.A. Borea 3H]-MRE 2029-F20, a selective antagonist radioligand for the human A2B adenosine receptors Bioorg. Med. Chem. Lett. 14 2004 3607 3610
45. M.R. Boarder, and S.M.O. Hourani The regulation of vascular function by P2 receptors: multiple site and multiple receptors Trends Pharmacol. Sci. 19 1998 99 107
46. F. Di Virgilio, P. Chiozzi, D. Ferrari, S. Falzoni, J.M. Sanz, A. Morelli, and M. Torboli Nucleotide receptors: an emerging family of regulatory molecules in blood cells Blood 97 2001 587 600
47. F. Di Virgilio The P2Z purinoreceptor: an intriguing role in immunity, inflammation and cell death Immun. Today 16 1995 524 528
48. B.S. Khakh, G. Burnstock, C. Kennedy, B.F. King, A. North, P. Śgúla, and M. Voight International Union of Pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits Pharmacol. Rev. 53 2001 107 118
49. F. Rassendren, G. Buell, C. Virginio, G. Collo, R.A. North, and A. Suprenant The permeabilizing ATP receptor P2X7: cloning of a human cDNA J. Biol. Chem. 272 1997 5482 5486
50. D. Ferrari, A. La Sala, P. Chiozzi, A. Morelli, S. Falzoni, and G. Girolomoni The P2 purinergic receptors of human dendritic cells: identification and coupling to cytokine release FASEB 14 2000 2466 2476
51. C.E. Gargett, and J.S. Wiley The isoquinoline derivative KN-62: a potent antagonist of the P2Z receptor of human lymphocytes Br. J. Pharmacol. 120 1997 1483 1490
52. B.D. Humphreys, C. Virginio, A. Surprenant, J. Rice, and G.R. Dubyak Isoquinolines as antagonists of the P2X7 nucleotide receptor: high selectivity for the human versus rat receptor homologues Mol. Pharmacol. 54 1998 22 32
53. P.G. Baraldi, R. Romagnoli, M.A. Tabrizi, S. Falzoni, and F. Di Virgilio Synthesis of conformationally constrained analogues of KN-62, a potent antagonist of the P2X7-receptor Bioorg. Med. Chem. Lett. 10 2000 681 684
54. P.G. Baraldi, R. Makaeva, M.G. Pavani, M.C. Nunez, G. Spalluto, S. Moro, and S. Falzoni Synthesis, biological activity and molecular modeling studies of 1,2,3,4-tetrahydroisoquinoline derivatives as conformationally constrained analogues of KN-62, a potent antagonist of the P2X7-receptor containing the tyrosine moiety Arzneimittel-Forschung/Drug Res. 52 2002 273 285
55. P.G. Baraldi, D.C. Nunez, M. Morelli, S. Falzoni, F. Di Virgilio, and R. Romagnoli Synthesis and biological activity of N-arylpiperazine-modified analogues of KN-62, a potent antagonist of the purinergic P2X7 receptor J. Med. Chem. 46 2003 1318 1329
56. R.G. Ravi, S.B. Kertesy, G.R. Dubyak, and K.A. Jacobson Potent P2X7 receptor antagonists: tyrosyl derivatives synthesized using a sequential parallel synthetic approach Drug Dev. Res. 54 2001 75 87